CIK 0001621227 · Non-accelerated filer<br>Smaller reporting company
Adaptimmune Therapeutics PLC
Sign in to watch- Ticker
- ADAPY
- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- United Kingdom
- Entity type
- operating
- Phone
- 44 1235 430000
- Business address
- 60 JUBILEE AVENUE, MILTON PARK, ABINGDON, OXFORDSHIRE, United Kingdom
- Former names
- Adaptimmune Ltd
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 10 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-07-05 | Menzel Garry E Director | Grant or award · Option to Purchase Ordinary Shares | +2,158,776 | 2,158,776 | ||
| 2023-07-03 | Behbahani Ali Director | Grant or award · Option to purchase Ordinary Shares | +933,317 | 933,317 | ||
| 2023-07-03 | Hegde Priti Director | Grant or award · Option to purchase Ordinary Shares | +500,000 | 500,000 | ||
| 2023-07-03 | Furey John Director | Grant or award · Option to purchase Ordinary Shares | +500,000 | 500,000 | ||
| 2023-07-03 | Menzel Garry E Director | Grant or award · Option to purchase Ordinary Shares | +981,463 | 981,463 | ||
| 2023-07-03 | Sigal Charles Elliott Director | Grant or award · Option to purchase Ordinary Shares | +933,317 | 933,317 | ||
| 2023-07-03 | Alleva Lawrence M Director | Grant or award · Option to purchase Ordinary Shares | +1,077,756 | 1,077,756 | ||
| 2023-07-03 | MOTT DAVID M Director | Grant or award · Option to purchase Ordinary Shares | +1,462,927 | 1,462,927 | ||
| 2023-07-03 | Allen Andrew R Director | Grant or award · Option to purchase Ordinary Shares | +500,000 | 500,000 | ||
| 2023-06-27 | Rawcliffe Adrian Chief Executive Officer | Sale | −2,333 | $0.92 | $2K | 3,519 |
| 2023-06-01 | Menzel Garry E Director | Grant or award | +200,646 | 200,646 | ||
| 2023-06-01 | Menzel Garry E Director | Grant or award | +200,647 | 200,647 | ||
| 2023-06-01 | Menzel Garry E Director | Grant or award | +209,931 | 209,931 | ||
| 2023-01-31 | Piccina Cintia Chief Commercial Officer | Sale | −11,890 | $1.87 | $22K | 19,535 |
| 2023-01-17 | Lunger John Chief Patient Supply Officer | Sale | −4,440 | $1.86 | $8K | 7,264 |
| 2023-01-17 | Bertrand William C JR Chief Operating Officer | Sale | −4,440 | $1.86 | $8K | 7,264 |
| 2023-01-17 | Norry Elliot Chief Medical Officer | Sale | −2,159 | $1.86 | $4K | 3,491 |
| 2023-01-17 | Rawcliffe Adrian Chief Executive Officer | Sale | −10,057 | $1.86 | $19K | 13,351 |
| 2023-01-17 | Bertrand William C JR Chief Operating Officer | Grant or award · Option to purchase Ordinary Shares | +1,407,072 | 1,407,072 | ||
| 2023-01-17 | Bertrand William C JR Chief Operating Officer | Grant or award · Option to purchase Ordinary Shares | +314,256 | 314,256 |
Page 6 of 23 · 454 trades